HIF-1α is a key mediator of the lung inflammatory potential of lithium-ion battery particles.


Journal

Particle and fibre toxicology
ISSN: 1743-8977
Titre abrégé: Part Fibre Toxicol
Pays: England
ID NLM: 101236354

Informations de publication

Date de publication:
18 09 2019
Historique:
received: 31 05 2019
accepted: 29 08 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 25 2 2020
Statut: epublish

Résumé

Li-ion batteries (LIB) are increasingly used worldwide. They are made of low solubility micrometric particles, implying a potential for inhalation toxicity in occupational settings and possibly for consumers. LiCoO By testing a set of 5 selected LIB particles (LCO, LiNiMnCoO We conclude that HIF-1α, stabilized in lung cells by released Co and Ni ions, is a mechanism-based biomarker of lung inflammatory responses induced by LIB particles containing Co/Ni. Documenting the Co/Ni content of LIB particles, their bioaccessibility and their capacity to stabilize HIF-1α in vitro can be used to predict the lung inflammatory potential of LIB particles.

Sections du résumé

BACKGROUND
Li-ion batteries (LIB) are increasingly used worldwide. They are made of low solubility micrometric particles, implying a potential for inhalation toxicity in occupational settings and possibly for consumers. LiCoO
RESULTS
By testing a set of 5 selected LIB particles (LCO, LiNiMnCoO
CONCLUSIONS
We conclude that HIF-1α, stabilized in lung cells by released Co and Ni ions, is a mechanism-based biomarker of lung inflammatory responses induced by LIB particles containing Co/Ni. Documenting the Co/Ni content of LIB particles, their bioaccessibility and their capacity to stabilize HIF-1α in vitro can be used to predict the lung inflammatory potential of LIB particles.

Identifiants

pubmed: 31533843
doi: 10.1186/s12989-019-0319-z
pii: 10.1186/s12989-019-0319-z
pmc: PMC6751682
doi:

Substances chimiques

Cytokines 0
Hif1a protein, mouse 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Ions 0
Oxides 0
lithium cobalt oxide 0
Cobalt 3G0H8C9362

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Références

Toxicology. 2011 May 10;283(2-3):65-87
pubmed: 21414382
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2013 Jul;31(7):481-6
pubmed: 24053909
Cancer Immunol Immunother. 2016 Oct;65(10):1159-67
pubmed: 27497816
Am Rev Respir Dis. 1984 Jul;130(1):130-5
pubmed: 6742597
Toxicol Appl Pharmacol. 1996 Feb;136(2):372-80
pubmed: 8619246
Biotechniques. 2008 Apr;44(4):507-11, 514-7
pubmed: 18476815
Nano Lett. 2015 Aug 12;15(8):5168-77
pubmed: 26176939
Part Fibre Toxicol. 2016 Feb 03;13:5
pubmed: 26843362
Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L575-82
pubmed: 10956633
Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1120-30
pubmed: 19801454
J Appl Toxicol. 1999 Mar-Apr;19(2):133-40
pubmed: 10215185
Mol Cancer Ther. 2008 Jan;7(1):90-100
pubmed: 18202012
Part Fibre Toxicol. 2014 Dec 13;11:69
pubmed: 25497724
J Cell Mol Med. 2016 Apr;20(4):688-97
pubmed: 26781174
J Natl Cancer Inst. 2013 Sep 4;105(17):1270-83
pubmed: 23940289
Inhal Toxicol. 2016 Aug;28(9):393-402
pubmed: 27240636
Nature. 2008 Jun 5;453(7196):807-11
pubmed: 18432192
Int J Mol Med. 2017 Jan;39(1):153-159
pubmed: 27909731
J Immunol. 1995 Sep 1;155(5):2459-67
pubmed: 7544377
Cell. 2001 Oct 5;107(1):43-54
pubmed: 11595184
Sci Total Environ. 2012 Aug 15;432:210-5
pubmed: 22732165
Toxicol In Vitro. 2015 Jun;29(4):722-6
pubmed: 25735930
J Biol Chem. 2003 May 2;278(18):15911-6
pubmed: 12606543
Mol Cell. 2010 Oct 22;40(2):294-309
pubmed: 20965423
Am J Respir Cell Mol Biol. 2001 Jun;24(6):740-6
pubmed: 11415940
Cancer Cell. 2004 Jul;6(1):33-43
pubmed: 15261140
Toxicol Sci. 2010 Aug;116(2):673-81
pubmed: 20511350
Cancer Res. 2003 Jul 1;63(13):3524-30
pubmed: 12839937
Sci Rep. 2012;2:481
pubmed: 22745900
Crit Rev Oncol Hematol. 2002 Apr;42(1):35-56
pubmed: 11923067
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18154-9
pubmed: 17114296
Mol Cancer. 2014 Apr 28;13:91
pubmed: 24775564
Environ Toxicol Chem. 2017 Sep;36(9):2493-2502
pubmed: 28295556
J Biol Chem. 1997 Aug 1;272(31):19253-60
pubmed: 9235919
Mol Cancer Ther. 2004 Mar;3(3):233-44
pubmed: 15026543
Part Fibre Toxicol. 2014 Mar 27;11:14
pubmed: 24669904
Materials (Basel). 2019 Apr 15;12(8):
pubmed: 30991665
Am J Respir Cell Mol Biol. 2001 Apr;24(4):368-75
pubmed: 11306428
Part Fibre Toxicol. 2013 Jul 30;10:33
pubmed: 23895460
ACS Nano. 2017 Jan 24;11(1):291-303
pubmed: 28045493
ACS Appl Mater Interfaces. 2017 Jun 14;9(23):19870-19880
pubmed: 28534410
Drug Metab Dispos. 2012 Oct;40(10):1953-65
pubmed: 22798553
Arch Toxicol. 2018 May;92(5):1673-1684
pubmed: 29550861
Nat Rev Immunol. 2009 Sep;9(9):609-17
pubmed: 19704417

Auteurs

Violaine Sironval (V)

Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue Hippocrate 57 - bte B1.57.06, 1200, Brussels, Belgium. violaine.sironval@uclouvain.be.

Mihaly Palmai-Pallag (M)

Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue Hippocrate 57 - bte B1.57.06, 1200, Brussels, Belgium.

Rita Vanbever (R)

Louvain Drug Research Institute, Université catholique de Louvain, Avenue Mounier 73 - bte B1.73.12, 1200, Brussels, Belgium.

François Huaux (F)

Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue Hippocrate 57 - bte B1.57.06, 1200, Brussels, Belgium.

Jorge Mejia (J)

Research Centre for the Physics of Matter and Radiation (PMR-LARN), NARILIS, Université de Namur, rue de Bruxelles 61, 5000, Namur, Belgium.

Stéphane Lucas (S)

Research Centre for the Physics of Matter and Radiation (PMR-LARN), NARILIS, Université de Namur, rue de Bruxelles 61, 5000, Namur, Belgium.

Dominique Lison (D)

Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue Hippocrate 57 - bte B1.57.06, 1200, Brussels, Belgium.

Sybille van den Brule (S)

Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue Hippocrate 57 - bte B1.57.06, 1200, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH